InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CEO Discusses Blockbuster Drug Potential on MidasLetter Podcast
November 18, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent MidasLetter Live podcast. Mydecine’s CEO and Chairman Joshua Bartch joined the program to provide an overview of the company and the science behind its psychedelic compounds. “What we are […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Featured in ROTH Equity Research Report
November 17, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are reiterating our Buy rating and C$3/share 12-month price target on Mydecine following the release of 3Q21 results. . . The highlight of the quarter was the announcement that Mydecine […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations
November 15, 2021
Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients In September, Mydecine filed its final patent […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum
November 10, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has announced that chief medical officer Dr. Rakesh Jetly will be part of the Horizons’ Veterans & Families Forum. The forum is scheduled for Nov. 10, and Jetly will be a […]
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event
November 5, 2021
Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled […]
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
November 4, 2021
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/8YBVv […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Patent Covering Formulations Featuring Nanoemulsion
November 3, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced that it has filed a technology patent protecting the creation of formulations that use nanoemulsion technology. The formulations aim to enhance, stabilize and make repeatable properties of ingredients from traditional […]
InvestorNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’
November 2, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics […]
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
November 2, 2021
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Breaking the Habit: Psychedelic Stigma Fades as […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation in November Event
October 29, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, will be participating in the Wonderland: Miami. Hosted by Microdose, the upcoming event is scheduled for Nov. 8–9, 2021, and will be held in Miami at the Adrienne Arsht Center for […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue
October 27, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved pharmaceutical properties to further strengthen MYCO’s library of patent-pending tryptamines. According to the announcement, the synthesis of the […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’
October 27, 2021
The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and […]
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
June 25, 2021
NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will consist of Virtual Panels on Emerging Therapeutics and select Fireside Chats with Roth Research Analysts. This format will provide an opportunity for C-level executives representing established private healthcare […]
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
June 25, 2021
Event to Feature Panels on Emerging Therapeutics & Fireside Chats with Biotechnology, Pharmaceuticals and Medical Technologies Focus NEWPORT BEACH, Calif., June. 25, 2021 — via InvestorWire — Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will consist of Virtual Panels on Emerging […]